Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 85 peer-reviewed journal articles Updated
Pulmonology

Mycobacterium avium complex (MAC): A Patient Guide

At a Glance

Pulmonary MAC is a chronic infection usually confirmed with compatible symptoms, CT findings, and repeated positive sputum cultures—not one test alone. When treatment is needed, several antibiotics, airway clearance, and monitoring often continue for 18 months or longer.

Mycobacterium avium complex (MAC) is a group of bacteria that live naturally all around us in the environment, particularly in soil, household dust, and water systems [1]. While these organisms are relatives of the bacteria that cause tuberculosis, MAC is fundamentally different: pulmonary MAC is generally not spread person-to-person, and encountering it is a normal part of daily life [2]. For most healthy individuals, breathing in these bacteria causes no harm; however, in people with underlying lung vulnerabilities—such as scarred airways from bronchiectasis—or severely weakened immune systems, the bacteria can settle into the lungs or spread throughout the body, causing a chronic infection [3][4].

Because MAC is so common in the environment, a diagnosis is never based on a single piece of evidence. A person might breathe in the bacteria one day and cough them out the next without being truly infected. To confirm a diagnosis of pulmonary MAC, doctors follow strict international guidelines that require a combination of evidence: compatible symptoms like a chronic cough or fatigue, specific patterns of inflammation or cavities on a CT scan, and repeated positive laboratory cultures [5][6]. One positive sputum test is not enough to confirm the disease; the bacteria must be found in at least two separate sputum samples (or one sterile biopsy/BAL) to suggest persistent infection rather than temporary colonization [7].

Living with MAC is often described as a marathon rather than a sprint. If treatment is necessary, it involves a long-term commitment to a combination of three or more antibiotics [6]. The goal of this treatment is “culture conversion,” which is generally defined as achieving three consecutive negative sputum cultures collected at least four weeks apart [8]. Standard guidelines recommend continuing these medications for at least 12 months after the date of your culture conversion, meaning the entire journey often lasts 18 months or longer [5][9]. This duration is necessary to help ensure sustained culture conversion and protect your lung function, as these bacteria are naturally slow-growing and resilient [10].

Beyond medications, successful long-term management focuses on protecting your body. Because the antibiotics are powerful, your care team will regularly monitor your vision, hearing, and liver health to catch any side effects early [11][12]. Simultaneously, you will likely learn daily airway clearance techniques to physically move mucus out of your lungs [13]. While the diagnosis can be overwhelming, most patients find that with a combination of specialist care, diligent monitoring, and individualized daily lung hygiene, they can manage the condition and maintain a high quality of life [14].

In this guide

6 chapters

01

Validation & Orientation for MAC Disease

Learn what a MAC disease diagnosis means, including lung risk factors, disease patterns, watchful waiting, antibiotic treatment, and long-term follow-up.

02

The Biology and Diagnosis of MAC

Learn how MAC lung disease is diagnosed using symptoms, CT scans, sputum cultures, AFB smears, and macrolide susceptibility testing. Repeat cultures may be needed.

03

Types, Symptoms, and Critical Warning Signs

Learn about pulmonary and disseminated MAC symptoms, nodular-bronchiectatic and fibrocavitary forms, and warning signs that need prompt or emergency care.

04

Treatment Options for Pulmonary MAC

Learn how pulmonary MAC is treated with combination antibiotics, susceptibility testing, culture monitoring, dosing schedules, and ALIS for refractory disease.

05

Treating Disseminated MAC and HIV Considerations

Learn about disseminated MAC treatment, including macrolides, ethambutol, ART timing, MAC-IRIS warning signs, and criteria for safely stopping medicines.

06

Side Effects, Monitoring, and Life with MAC

Learn how Mycobacterium avium complex (MAC) treatment is monitored, including medication side effects, sputum cultures, airway clearance, and daily self-care.

Common questions in this guide

What is MAC disease, and is it contagious?
Mycobacterium avium complex bacteria are common in soil, dust, and water systems, and pulmonary MAC is generally not spread from person to person. Most healthy people do not become ill after exposure, but people with vulnerable lungs or severely weakened immune systems can develop disease.
How is pulmonary MAC diagnosed?
Doctors usually combine compatible symptoms, characteristic changes on a CT scan, and repeated positive laboratory cultures. One positive sputum sample alone does not usually confirm disease; MAC generally must be found in at least two separate sputum samples or in one sterile biopsy or bronchoalveolar lavage sample.
Does a MAC diagnosis always mean I need antibiotics immediately?
Not always; the decision depends on your symptoms, CT findings, culture results, lung changes, and overall health. Your care team may discuss structured observation in some situations, while treatment is more likely when the disease is causing concerning or progressive problems.
What does culture conversion mean in MAC treatment?
Culture conversion generally means that three consecutive sputum cultures are negative, with samples collected at least four weeks apart. Treatment is typically continued for at least 12 months after the conversion date, so the full course may last 18 months or longer.
What health checks are needed during MAC antibiotic treatment?
Because MAC antibiotics can cause important side effects, the care team may regularly monitor your vision, hearing, and liver health. Your clinicians will determine the monitoring schedule based on the medicines you take and your individual health needs.
How can airway clearance help with MAC lung disease?
Airway clearance techniques help physically move mucus out of the lungs and are an important part of long-term management for many patients. A clinician can help choose methods suited to your type of lung involvement and teach you how to use them safely.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my CT scan and sputum cultures, do I meet the full criteria for a MAC diagnosis?
  2. 2.Is it safe for me to observe my symptoms with a structured follow-up plan, or do I need to start the antibiotic regimen immediately?
  3. 3.What is my 'culture conversion' goal, and how will we track the required three consecutive negative cultures?
  4. 4.Which airway clearance techniques are best suited for my specific type of lung involvement?
  5. 5.What is the personalized plan for monitoring my vision, hearing, and liver health while I am on treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Infection Sources of a Common Non-tuberculous Mycobacterial Pathogen, Mycobacterium avium Complex.

    Nishiuchi Y, Iwamoto T, Maruyama F

    Frontiers in medicine 2017; (4()):27 doi:10.3389/fmed.2017.00027.

    PMID: 28326308
  2. 2

    Vanadium in groundwater aquifers increases the risk of MAC pulmonary infection in O'ahu, Hawai'i.

    Lipner EM, French JP, Nelson S, et al.

    Environmental epidemiology (Philadelphia, Pa.) 2022; (6(5)):e220 doi:10.1097/EE9.0000000000000220.

    PMID: 36249270
  3. 3

    Showering is associated with Mycobacterium avium complex lung disease: An observational study in Japanese women.

    Uwamino Y, Nishimura T, Sato Y, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2020; (26(3)):211-214 doi:10.1016/j.jiac.2019.09.003.

    PMID: 31604605
  4. 4

    The Mycobacterium avium complex - an underestimated threat to humans and animals.

    Kaczmarkowska A, Didkowska A, Kwiecień E, et al.

    Annals of agricultural and environmental medicine : AAEM 2022; (29(1)):22-27 doi:10.26444/aaem/136398.

    PMID: 35352901
  5. 5

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  6. 6

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  7. 7

    Limited value of transbronchial lung biopsy for diagnosing Mycobacterium avium complex lung disease.

    Sekine A, Saito T, Satoh H, et al.

    The clinical respiratory journal 2017; (11(6)):1018-1023 doi:10.1111/crj.12459.

    PMID: 26808915
  8. 8

    Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.

    Griffith DE, Eagle G, Thomson R, et al.

    American journal of respiratory and critical care medicine 2018; (198(12)):1559-1569 doi:10.1164/rccm.201807-1318OC.

    PMID: 30216086
  9. 9

    [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].

    Wagner D, Lange C

    Deutsche medizinische Wochenschrift (1946) 2020; (145(16)):1145-1151 doi:10.1055/s-0043-124159.

    PMID: 32791550
  10. 10

    Mycobacterium avium complex: Adherence as a way of life.

    Falkinham JO

    AIMS microbiology 2018; (4(3)):428-438 doi:10.3934/microbiol.2018.3.428.

    PMID: 31294225
  11. 11

    Medications and Monitoring in Treatment of Nontuberculous Mycobacterial Pulmonary Disease.

    Sawka A, Burke A

    Clinics in chest medicine 2023; (44(4)):815-828 doi:10.1016/j.ccm.2023.06.012.

    PMID: 37890918
  12. 12

    Pharmacotherapy for nontuberculous mycobacterial pulmonary disease.

    Velagapudi M, Sanley MJ, Ased S, et al.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2022; (79(6)):437-445 doi:10.1093/ajhp/zxab422.

    PMID: 34788375
  13. 13

    Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review.

    Youssefnia A, Pierre A, Hoder JM, et al.

    Journal of thoracic disease 2022; (14(9)):3575-3597 doi:10.21037/jtd-22-410.

    PMID: 36245600
  14. 14

    The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.

    Kwon BS, Lee JH, Koh Y, et al.

    Respiratory medicine 2019; (150()):45-50 doi:10.1016/j.rmed.2019.02.007.

    PMID: 30961950

This page about Mycobacterium avium complex disease is for informational purposes only and does not constitute medical advice. Your clinician should interpret your tests and tailor monitoring and treatment to your needs.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.